The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase III Findings for Lenvatinib in HCC

Ann-Lii Cheng, MD
Published Online:8:02 PM, Mon July 10, 2017

Ann-Lii Cheng, MD, distinguished professor, department of Internal Medicine, Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses a phase III trial of lenvatinib (Lenvima) vs sorafenib (Nexavar) in the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.